TIDMAVCT

RNS Number : 6792N

Avacta Group PLC

21 January 2019

21 January 2019

Avacta Group plc

("Avacta", the "Group" or the "Company")

Result of Annual General Meeting

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.

The full text of each resolution is set out in the Notice of Annual General Meeting, included in the 2018 Annual Report, which is available on the Company's website www.avacta.com.

- Ends -

For further information from Avacta Group plc, please contact:

 
 Avacta Group plc                           Tel: +44 (0) 844 414 0452 
  Alastair Smith, Chief Executive            https://www.avacta.com 
  Officer 
  Tony Gardiner, Chief Financial Officer 
 finnCap Ltd                                Tel: +44 (0) 207 220 0500 
  Geoff Nash / Giles Rolls - Nominated       www.finncap.com 
  Adviser 
  Tim Redfern - ECM 
                                             Tel: +44 (0) 203 705 9318 
  WG Partners                                Tel: +44 (0) 203 705 9217 
  Nigel Birks / Nigel Barnes                 www.wgpartners.co.uk 
  David Wilson / Claes Spang 
 Turner Pope Investments                    Tel: 020 3621 4120 
  James Pope                                 james@turnerpope.com 
 
  Zyme Communications (Trade and Regional    Tel: +44 (0)7787 502 947 
  Media)                                     katie.odgaard@zymecommunications.com 
  Katie Odgaard 
 
  Yellow Jersey (Financial Media and         Tel: +44 (0)7764 947137 
  IR)                                        Tel: +44 (0)7544 275882 
  Sarah Hollins                              avacta@yellowjerseypr.com 
  Harriet Jackson

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer(R) technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer(R) technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer(R) reagents through licensing to developers of life sciences research tools and diagnostics.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGPGUPWGUPBGAG

(END) Dow Jones Newswires

January 21, 2019 10:40 ET (15:40 GMT)

Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Avacta Charts.
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Avacta Charts.